Suppr超能文献

通过将外周血淋巴细胞(PBLs)与负载同种异体肽/HLA/IgG1-Fc融合蛋白的自体单核细胞共培养产生的同种异体限制性细胞毒性T淋巴细胞(CTLs)。

Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.

作者信息

Weng Xiufang, Lu Shengjun, Zhong Maohua, Liang Zhihui, Shen Guanxin, Chen Jianguo, Wu Xiongwen

机构信息

Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

J Leukoc Biol. 2009 Mar;85(3):574-81. doi: 10.1189/jlb.0408242. Epub 2008 Dec 26.

Abstract

The graft-versus-leukemia effect of allogeneic marrow transplantation suggests the dramatic effect of the allogeneic T cell to eradicate malignant disease. Preparation and adoptive transfusion of tumor-specific T cells from HLA-mismatched donors might be expected to circumvent CTL tolerance to the tumor. In this study, a soluble, divalent HLA-A2 molecule was constructed with the Fc part of human IgG1 and was pulsed with a peptide related to melanoma tyrosinase 368-376 [Tyr(368-376) (Tyr)] to form the Tyr/HLA-A2 dimer, which allowed loading onto monocytes via interaction of the Fc and FcR. The HLA-A2-negative (HLA-A2-ve) monocytes loaded with the Tyr/HLA-A2 dimer acted as allo-APC with copies of a single allogeneic epitope. After coculture of the HLA-A2-ve PBLs and autologous monocytes loaded with the dimer, CD8+ cells in the coculture show an obvious proliferation and increased frequency of Tyr/HLA-A2 tetramer-stained cells. The sorted Tyr/HLA-A2 tetramer-positive CD8+ cells display an elevated cytotoxic activity against HLA-A2-positive melanoma cells expressing tyrosinase endogenously (i.e., SK-Mel-5) but little against tyrosinase-negative melanoma cells (i.e., A375). The coculture of PBLs and autologous monocytes loaded with allogeneic peptide/HLA complexes offers a novel approach to expand allo-restricted, peptide-specific CTLs, which might be a potential arsenal for treatment of patients with malignant disease, if the tumor-related epitope were defined.

摘要

异基因骨髓移植的移植物抗白血病效应表明异基因T细胞根除恶性疾病的显著作用。来自HLA不匹配供体的肿瘤特异性T细胞的制备和过继性输血可能有望规避CTL对肿瘤的耐受性。在本研究中,构建了一种可溶性二价HLA-A2分子,其与人IgG1的Fc部分相连,并用与黑色素瘤酪氨酸酶368 - 376 [Tyr(368 - 376)(Tyr)]相关的肽脉冲处理,形成Tyr/HLA-A2二聚体,该二聚体可通过Fc与FcR的相互作用加载到单核细胞上。负载Tyr/HLA-A2二聚体的HLA-A2阴性(HLA-A2-ve)单核细胞作为具有单个同种异体表位拷贝的同种异体抗原呈递细胞(allo-APC)。将HLA-A2-ve外周血淋巴细胞(PBLs)与负载二聚体的自体单核细胞共培养后,共培养物中的CD8 +细胞显示出明显的增殖,并且Tyr/HLA-A2四聚体染色细胞的频率增加。分选的Tyr/HLA-A2四聚体阳性CD8 +细胞对内源性表达酪氨酸酶的HLA-A2阳性黑色素瘤细胞(即SK-Mel-5)具有增强的细胞毒性活性,但对酪氨酸酶阴性的黑色素瘤细胞(即A375)几乎没有细胞毒性活性。PBLs与负载同种异体肽/HLA复合物的自体单核细胞的共培养提供了一种新方法来扩增同种异体限制性、肽特异性CTL,如果确定了肿瘤相关表位,这可能是治疗恶性疾病患者的潜在武器库。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验